PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: air traffic controller

ICH guideline E2F on development safety update report

September 2011 EMA/CHMP/ICH/309348/2008 ICH guideline E2F on development safety update report Step 5 Transmission to CHMP June 2008 Adoption by CHMP for release for consultation June 2008 End of consultation (deadline for comments) December 2008 Final adoption by CHMP September 2010 Date for coming into effect September 2011 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail Website European Medicines Agency, 2013.

crucial to the ongoing assessment of risk to trial subjects. 3, 4. It is also important to inform regulators and other interested parties (e.g., ethics committees) at regular intervals about the results of such ... Some national and regional laws and regulations also require a periodic report that describes the status of ongoing individual ...

Fullscreen Download
Loading..

Tags:

  Assessment, Risks, Regional

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of ICH guideline E2F on development safety update report

Documents from same domain

Q12 Step 2b Technical and regulatory …

www.ema.europa.eu

ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36

  Product, Management, Lifecycle, Product lifecycle management

Guideline on good pharmacovigilance practices …

www.ema.europa.eu

9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)

  Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance

Guideline on good pharmacovigilance practices (GVP)

www.ema.europa.eu

Guideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25

  Good, Practices

Guideline on good pharmacovigilance practices …

www.ema.europa.eu

Guideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28

  Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance

Guideline for good clinical practice E6(R2)

www.ema.europa.eu

Guideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification

  Good, Practices, Clinical, Good clinical practice

Guideline for good clinical practice E6(R2)

www.ema.europa.eu

Guideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November

  Guidelines, Good, Practices, Clinical, Good clinical practice e6

Guideline on good pharmacovigilance practices …

www.ema.europa.eu

harmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product

  Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance

European Medicines Agency

www.ema.europa.eu

© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline

  Guidelines, European, Agency, Medicine, Harmonised, European medicines agency, Ich harmonised

products1/traditional herbal medicinal products

www.ema.europa.eu

There is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already

  Product, Medicinal, Traditional, Herbal, Products1 traditional herbal medicinal products, Products1

Q7 Q&A - good manufacturing practice for active ...

www.ema.europa.eu

ICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37

  Good, Practices, Pharmaceutical, Manufacturing, Active, Ingredients, Good manufacturing practice for active, Good manufacturing practice for active pharmaceutical ingredients

Related documents

Fact Sheet 2: National Security Risk Assessment - GOV.UK

assets.publishing.service.gov.uk

How the National Security Risk Assessment (NSRA) was carried out Fact Sheet 2: National Security Risk Assessment The NSRA was designed to compare, ... • An attack on a UK overseas territory as the result of a sovereignty dispute or a wider regional conflict. • Short to medium term disruption to international supplies of resources (e.g. food ...

  Assessment, Risks, Regional, Risk assessment

December 3, 2021 DHDTC DAL 21-12 Dear Hospital Chief ...

coronavirus.health.ny.gov

Dec 03, 2021 · Assessment The assessment below will be used on a weekly basis to determine the Impacted Facilities List. 1. High risk regional assessment (defined as “High Risk Regions”): • Low current regional capacity: Staffed acute bed occupancy rate for the region at [90%] or higher (based on the previous 7-day average); OR

  Assessment, Risks, Regional, Regional risk assessment

Chapter 4 Flood Risk Assessment - FEMA

training.fema.gov

———Flood Risk Assessment——— 4-2 Risk Assessment The occupancy or use of flood-prone areas involves a degree of risk. Risk is exposure to an undesired event. It can be expressed in probability that the event will happen, often during a calendar year. Probability is a numerical index of risk; it is a measure of the likelihood that the ...

  Assessment, Risks, Risk assessment

Care Assessment Need (CAN) Score and the Patient Care ...

www.hsrd.research.va.gov

Jun 27, 2013 · Care Assessment Need (CAN) Score • Reflects estimated probability of admission or death within a specified time period (90 days or 1 year) • Expressed as a percentile, ranging from 0 (lowest risk) to 99 (highest risk) • Indicates how a given Veteran compares with other individuals in terms of likelihood of hospitalization or death

  Assessment, Risks

NCCN Clinical Practice Guidelines in Oncology NCCN ...

www2.tri-kobe.org

Updates in Version 1.2019 of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian from Version 1.2018 include: Li-Fraumeni Syndrome LIFR-A 1 of 2 • Breast Cancer Risk for Women 4th bullet was revised from, “Discuss option of risk-reducing mastectomy and counsel regarding degree of protection, degree of

  Assessment, Guidelines, Risks, Risk assessment, Nccn, Nccn guidelines

Hypertension Canada's 2020 Comprehensive Guidelines …

guidelines.hypertension.ca

risk assessment, and treatment of hypertension in adults and children provide comprehensive, evidence-based guidance for health care pro-fessionals and patients. Hypertension Canada develops the guidelines using rigourous methodology, carefully mitigatingthe risk of bias in our process. All draft recommendations undergo critical review by expert

  Assessment, Guidelines, Risks, Comprehensive, 2200, Canada, Risk assessment, Hypertension, Hypertension canada s 2020 comprehensive guidelines

M4E(R2) - Common technical document for the registration ...

www.ema.europa.eu

2.5.6.4 Benefit-Risk Assessment 2.5.6.5 Appendix 2.5.7 Literature References Detailed discussion of content of the clinical overview sections 2.5.1 Product development rationale The discussion of the rationale for the development of the medicinal product should: Identify the pharmacological class of the medicinal product.

  Assessment, Risks, Risk assessment

Related search queries

Risk Assessment, Regional, Assessment, Risk regional assessment, Risk, Guidelines, NCCN Guidelines, Hypertension Canada's 2020 Comprehensive Guidelines